(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -10.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Biontech Se's revenue in 2025 is $3,665,697,674.On average, 25 Wall Street analysts forecast BNTX's revenue for 2025 to be $544,631,594,250, with the lowest BNTX revenue forecast at $379,438,700,100, and the highest BNTX revenue forecast at $839,189,520,500. On average, 24 Wall Street analysts forecast BNTX's revenue for 2026 to be $596,329,516,000, with the lowest BNTX revenue forecast at $372,946,402,950, and the highest BNTX revenue forecast at $815,865,341,850.
In 2027, BNTX is forecast to generate $637,447,397,950 in revenue, with the lowest revenue forecast at $415,987,928,500 and the highest revenue forecast at $854,338,213,850.